BioSpace News Archive

Tasrif Pharmaceutical announces the grant of a US Patent related to its proprietary humanized monoclonal antibodies against the poliovirus receptor (a.k.a. CD155). Poliovirus Receptor (PVR) is overexpressed on many malignancies including cancers of the brain, breast, colon and pancreas.

Ryvu Therapeutics (WSE: RVU) announced today that the first patient enrolled in the Phase I/II clinical trial investigating RVU120 (SEL120) in relapsed/refractory metastatic or advanced solid tumors, has received the first dose of the study drug.

Millar, Inc., a leader in the field of high-fidelity, MEMS based pressure catheter technology and Schwarzer Cardiotek a leader in the field of Electrophysiology measurement systems, are pleased to announce their strategic partnership to promote the direct connection between the Millar Mikro-Cath and the EP-Tracer recording system.

Opiant Pharmaceuticals, Inc. announced that members of the company’s senior management team will participate in the following virtual investor conferences

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has completed a strategic investment in Trice Medical, Inc., a company focused on developing and commercializing minimally invasive technologies for sports medicine and orthopedic surgical procedures.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced positive topline results from the pivotal Phase 3 RISE-PD clinical trial that evaluated the novel formulation, IPX-203, in patients with Parkinson’s disease (PD) who have motor fluctuations.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will relocate both its corporate headquarters and the Personalis Clinical Laboratory from Menlo Park to 6600 Dumbarton Circle in Fremont.

Bayer, a leader in women’s healthcare, today announced the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) that extends the duration of use for its market leading1 intrauterine device (IUD) Mirena®.

OptiNose, Inc., a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced that the company has granted non-qualified stock option awards to purchase an aggregate of 60,000 shares of its common stock to seven new employees as an inducement material for accepting employment with OptiNose.

NovaRock Biotherapeutics Limited, a clinical-stage biopharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, today announced that they have entered into an exclusive license agreement and strategic partnership with Flame Biosciences.